OracleBio to highlight Oncology image analysis expertise at Tumor Models conference

OracleBio, providers of high precision digital image analysis services for detailed quantification of histological marker staining within cells and tissues, is pleased to announce it will be a principal sponsor of the forthcoming Tumor Models conference to be held in Boston, MA on the 23-25th July.

At the conference OracleBio’s Chief Scientific Officer, Dr Lorcan Sherry, will also deliver a presentation entitled ‘Detailed Quantification of Drug Response Read-outs in Tumor Xenograft Tissue using Whole Slide Digital Image Analysis’, which will highlight OracleBio’s expertise in using Definiens Tissue Studio™ for quantification of common Xenograft drug efficacy parameters.

Using state of the art Definiens image analysis software, OracleBio can deliver accurate and consistent quantification of histological, IHC and ISH marker staining on a cell-by-cell basis. The company have extensive experience of tumor xenograft analysis, covering a wide range of drug response read-outs including viable and necrotic content, mechanistic markers (proliferation, microvessel density, apoptosis, DNA damage and more) and specific biomarker expression within sub-cellular compartments (nucleus, cytoplasm and membrane).

“Our client base now includes some of the world’s largest pharmaceutical companies,” explains Dr John Waller, COO of OracleBio ”and with over 75 years’ management experience of working within Pharma R&D, biomarker research and image analysis, OracleBio brings a wealth of expertise and value to its customers by combining scientific excellence and Definiens image analysis solutions”.

Dr Sherry continues “Our customers clearly benefit from the high data quality and fast turn-around times we can deliver using Definiens Tissue Studio™, which is considered the industry gold standard image analysis software”.

OracleBio’s success is reflected in a recent expansion of its workforce to include two new business development managers based in the USA and Europe, who aim to enhance the provision of image analysis services within Pharma R&D, diagnostics development, digital pathology and biomarker research.

Source: http://www.oraclebio.com/